重组组织型纤溶酶原激活剂联合依达拉奉治疗急性脑梗死临床疗效观察

目的观察重组组织型纤溶酶原激活剂（rtPA）联合依达拉奉治疗急性脑梗死的临床疗效及安全性。方法选择25例急性脑梗死病人,同时选择25例具有可比性的病例作为对照组。治疗组给予rtPA联合依达拉奉治疗,对照组给予丹参注射液治疗。以欧洲脑卒中临床神经缺损评分标准（ESS）和Barthel指数进行疗效评定。结果治疗后24h、21d的ESS积分治疗组明显高于对照组,差异有显著性;治疗组疗效明显优于对照组。结论rtPA联合依达拉奉治疗急性脑梗死安全有效,能显著改善患者的预后。

Therapeutic efficacy of rtPA-edaravone combination on acute cerebral infarction

Objective To investigate the therapeutic efficacy and safety of rtPA-edaravone combination on acute cerebral infarction（ACI）.Methods Twenty-five cases of ACI were selected for study in comparison with 25 cases with comparability as controls.The patients in treatment group were treated with rtPA-edaravone combination,and patients in control group were only treated with Danshen（Radix Salviae Miltiorrhizae）Injection.The neurologic function deficits of patients in both groups were evaluated by ESS and Barthel index before and after the treatment respectively.Results ESS integral of 24 hours,21 days after treatment was high in treatment group was significantly higher than that of patients in control group.The effective rate of patients in treatment group was significantly higher than that of patients in control group.Conclusion The rtPA-edaravone combination is effective in improvement of neurological function and ability of daily living for patients with acute cerebral infarction within 24 h of onset.